Literature DB >> 19854477

Relationship between prostate-specific antigen and hematocrit: does hemodilution lead to lower PSA concentrations in men with a higher body mass index?

Kazuhiro Ohwaki1, Fumiyasu Endo, Osamu Muraishi, Sonoe Hiramatsu, Eiji Yano.   

Abstract

OBJECTIVES: To examine whether a lower hematocrit was associated with a lower prostate-specific antigen (PSA), when stratifying by body mass index (BMI) in healthy men. PSA test is widely used in screening for prostate cancer. Many studies have found that PSA levels inversely correlate with BMI. It remains unclear whether hemodilution causes this inverse relationship.
METHODS: We investigated 19,367 men who visited a hospital for a routine health checkup in 2007. We obtained information on age, BMI, PSA, hematocrit, and smoking status. BMI was categorized as < 18.5, 18.5-22.0, 22.0-25.0, 25.0-30.0, and > or = 30.0 kg/m(2).
RESULTS: In all subjects, older age and lower BMI were weakly correlated with a higher PSA (r = 0.20, P <.001 and r = -0.05, P <.001, respectively). A multiple regression model for predicting PSA was constructed using age, current smoking status, and hematocrit for each BMI category. After controlling for age and smoking, PSA increased significantly with increasing hematocrit in participants with BMIs of 18.5-30 kg/m(2) (all P <.001). For example, in men with a BMI of 22-25 kg/m(2), slight increases (1.4% increase; 95% confidence interval, 1.0%-1.9%) were observed in PSA with a 1-unit increase in hematocrit.
CONCLUSIONS: In healthy men with a BMI of 18.5-30 kg/m(2), a lower hematocrit was significantly associated with a lower PSA. Hemodilution may explain the lower PSA levels observed in men with a higher BMI, resulting in an inverse relationship between BMI and PSA. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19854477     DOI: 10.1016/j.urology.2009.06.099

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

2.  Case-only gene-environment interaction between ALAD tagSNPs and occupational lead exposure in prostate cancer.

Authors:  Christine Neslund-Dudas; Albert M Levin; Andrew Rundle; Jennifer Beebe-Dimmer; Cathryn H Bock; Nora L Nock; Michelle Jankowski; Indrani Datta; Richard Krajenta; Q Ping Dou; Bharati Mitra; Deliang Tang; Benjamin A Rybicki
Journal:  Prostate       Date:  2014-02-05       Impact factor: 4.104

Review 3.  A stage-dependent link between metabolic syndrome components and incident prostate cancer.

Authors:  Jan Hammarsten; Jan-Erik Damber; Mohammad A Haghsheno; Dan Mellström; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

4.  Role of PSA density in diagnosis of prostate cancer in obese men.

Authors:  Peter Ka-Fung Chiu; Jeremy Yuen-Chun Teoh; Samson Yun-Sang Chan; Peggy Sau-Kwan Chu; Chi-Wai Man; See-Ming Hou; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2014-09-09       Impact factor: 2.370

5.  Relationship between prostate-specific antigen levels and ambient temperature.

Authors:  Kazuhiro Ohwaki; Fumiyasu Endo; Kazunori Hattori; Osamu Muraishi
Journal:  Int J Biometeorol       Date:  2013-05-10       Impact factor: 3.787

6.  Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies.

Authors:  A S Parker; D D Thiel; E Bergstralh; R E Carlson; L J Rangel; R W Joseph; N Diehl; R J Karnes
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-08-20       Impact factor: 5.554

7.  Association between carcinoembryonic antigen, carbohydrate antigen 19-9 and body mass index in colorectal cancer patients.

Authors:  Wei Chen; Qin Liu; Shu-Yun Tan; Yan-Hui Jiang
Journal:  Mol Clin Oncol       Date:  2013-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.